{"id":51741,"date":"2025-12-21T21:35:44","date_gmt":"2025-12-21T13:35:44","guid":{"rendered":"https:\/\/flcube.com\/?p=51741"},"modified":"2025-12-21T21:35:45","modified_gmt":"2025-12-21T13:35:45","slug":"epi-003-wins-fda-ind-as-first-lnp-epigenetic-therapy-for-hepatitis-b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51741","title":{"rendered":"EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B"},"content":{"rendered":"\n

Epigenic Therapeutics (Shanghai) Biotechnology Co., Ltd.<\/strong>, a clinical\u2011stage biotech focused on epigenetic modulation therapies, announced that EPI-003<\/strong>, the world’s first epigenetic regulatory therapy based on lipid nanoparticle (LNP) delivery<\/strong>, received Investigational New Drug (IND) approval<\/strong> from the U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of chronic hepatitis B<\/strong>. The drug is currently in Phase\u202f1 trials in New Zealand, Australia, and Hong\u202fKong SAR.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>19\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>U.S. FDA<\/td><\/tr>
Product<\/strong><\/td>EPI\u2011003<\/td><\/tr>
Innovation<\/strong><\/td>World’s first LNP\u2011delivered epigenetic regulatory therapy<\/td><\/tr>
Indication<\/strong><\/td>Chronic hepatitis B<\/td><\/tr>
Mechanism<\/strong><\/td>LNP delivers mRNA encoding epigenetic regulatory proteins + guide RNAs to liver cells<\/td><\/tr>
Target<\/strong><\/td>Covalently closed circular DNA (cccDNA) and integrated HBV DNA<\/td><\/tr>
Effect<\/strong><\/td>Induces long\u2011lasting epigenetic modifications, suppressing viral transcription<\/td><\/tr>
Clinical Stage<\/strong><\/td>Phase\u202f1 trials underway in New\u202fZealand, Australia, Hong\u202fKong SAR<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>EPI\u2011003<\/th>Competitive Landscape<\/th><\/tr><\/thead>
Technology<\/strong><\/td>LNP\u2011delivered mRNA encoding epigenetic regulators<\/td>Novel approach vs. nucleoside analogs and siRNAs<\/td><\/tr>
Mechanism<\/strong><\/td>Direct epigenetic silencing of cccDNA\/integrated DNA<\/td>Addresses viral reservoir, not just replication<\/td><\/tr>
Preclinical Efficacy<\/strong><\/td>Significant and sustained reduction in HBsAg and HBV DNA<\/td>Maintains efficacy post\u2011treatment discontinuation<\/td><\/tr>
Clinical Potential<\/strong><\/td>Functional cure and potential complete cure<\/td>Current therapies rarely achieve HBsAg loss<\/td><\/tr>
Innovation<\/strong><\/td>First epigenetic therapy<\/strong> for HBV globally<\/td>Positions Epigenic as leader in viral epigenetics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
Global HBV Prevalence<\/strong><\/td>300\u202fmillion<\/strong> chronically infected (WHO)<\/td>870,000<\/strong> annual deaths from HBV\u2011related complications<\/td><\/tr>
China HBV Market<\/strong><\/td>\u00a515\u201120\u202fbillion<\/strong> (\u2248\u202fUS$2.1\u20112.8\u202fB)<\/td>Dominated by nucleoside analogs (entecavir, tenofovir)<\/td><\/tr>
Functional Cure Rate<\/strong><\/td><5% with current SOC<\/td>High unmet need for therapies achieving HBsAg loss<\/td><\/tr>
EPI\u2011003 Peak Sales<\/strong><\/td>\u00a55\u20118\u202fbillion<\/strong> (\u2248\u202fUS$700\u202fM\u20111.1\u202fB) globally by 2035<\/td>If approved, could capture 20\u201130% of China HBV market<\/td><\/tr>
Competitive Advantage<\/strong><\/td>Epigenetic silencing<\/strong> of viral reservoir<\/td>Differentiated from replication\u2011inhibiting agents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n